Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

NingYu Wang

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|March 30, 2020
Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic AbnormalityYing Xu, Qianqian Wang, Kunjie Xiao, et al.
Plos One|January 14, 2014
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer modelTinghong Ye, Ying Xiong, Yupeng Yan, et al.
Journal of Medicinal Chemistry|January 24, 2023
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian CancerQiangsheng Zhang, Xinyi Chen, Jiaying Cao, et al.
Cell Death & Disease|October 20, 2018
YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defectQian Lei, Lu Xiong, Yong Xia, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2016
Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agentsKai Ran, Chao Gao, Hongxia Deng, et al.
European Journal of Medicinal Chemistry|June 30, 2019
Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitisYaojie Shi, Qianqian Wang, Juan Rong, et al.
Journal of Medicinal Chemistry|February 19, 2021
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Zhihao Liu, Xi Hu, Qiwei Wang, et al.
Journal of Medicinal Chemistry|November 30, 2022
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of CancerGuoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, et al.
Scientific Reports|July 14, 2016
Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosisChao Gao, Cuiting Peng, Yaojie Shi, et al.
Scientific Reports|February 13, 2016
Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancerXuejiao Song, Tiantao Gao, Ningyu Wang, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|March 30, 2020
Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic AbnormalityYing Xu, Qianqian Wang, Kunjie Xiao, et al.
Plos One|January 14, 2014
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer modelTinghong Ye, Ying Xiong, Yupeng Yan, et al.
Journal of Medicinal Chemistry|January 24, 2023
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian CancerQiangsheng Zhang, Xinyi Chen, Jiaying Cao, et al.
Cell Death & Disease|October 20, 2018
YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defectQian Lei, Lu Xiong, Yong Xia, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2016
Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agentsKai Ran, Chao Gao, Hongxia Deng, et al.
European Journal of Medicinal Chemistry|June 30, 2019
Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitisYaojie Shi, Qianqian Wang, Juan Rong, et al.
Journal of Medicinal Chemistry|February 19, 2021
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Zhihao Liu, Xi Hu, Qiwei Wang, et al.
Journal of Medicinal Chemistry|November 30, 2022
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of CancerGuoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, et al.
Scientific Reports|July 14, 2016
Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosisChao Gao, Cuiting Peng, Yaojie Shi, et al.
Scientific Reports|February 13, 2016
Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancerXuejiao Song, Tiantao Gao, Ningyu Wang, et al.
Pageof 10